NewsBenzingaPharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals Benzinga 2026.10.14 06:07 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
